Dr. Lewis Blevins' book emphasizes the importance of broadening awareness of Cushing’s Syndrome and its diagnosis. In his latest work, the PITUITARY WORLD NEWS co-founder shares his perspective on #hypercortisolism and highlights the challenges patients face on their diagnostic journeys. You can find more information on the book here: https://lnkd.in/gZbp2v3J #endocrinology
Corcept Therapeutics
Biotechnology Research
Menlo Park, CA 34,805 followers
Pioneering the discovery and development of cortisol modulators.
About us
At the center of discovery and development of cortisol modulation. Our mission is to unlock the potential of cortisol and revolutionize the treatment of serious diseases. For the last 25 years, we’ve led the way in the research and development of selective glucocorticoid receptors (GR) antagonists, molecules that alter GR and regulate cortisol levels. In 2012, we received FDA approval of a groundbreaking cortisol receptor blocker and the first approved treatment for hypercortisolism (Cushing’s syndrome). Today, global partnerships and collaborations form the bedrock of our robust development programs, including more than 500 GR antagonists for conditions spanning oncology, endocrine, and an array of metabolic disorders. What began as a ripple of scientific truth is now poised to unleash a sea change of discovery representing a fundamental shift in the way we understand and treat disease. We embrace possibility. We are Corcept.
- Website
-
http://www.corcept.com
External link for Corcept Therapeutics
- Industry
- Biotechnology Research
- Company size
- 201-500 employees
- Headquarters
- Menlo Park, CA
- Type
- Public Company
- Founded
- 1998
Locations
-
Primary
149 Commonwealth Dr
Menlo Park, CA 94025, US
Employees at Corcept Therapeutics
Updates
-
#Hypercortisolism in adults with difficult-to-control type 2 #diabetes might be more prevalent than previously thought. Check out this article in Healio by Michael Monostra that includes data from our CATALYST trial: https://lnkd.in/gk_WqXA2 #ADA2024 #ADAScientificSessions #T2D
Hypercortisolism prevalent among 24% of adults with difficult-to-control type 2 diabetes
healio.com
-
#CushingsSyndrome, or #hypercortisolism, is often misunderstood and misdiagnosed. Stories like Ana’s are important to increase awareness and help patients get the right care. Thank you PITUITARY WORLD NEWS for sharing. #endocrinology
Ana’s story highlights adrenal diseases and the fact that some people with high cortisol levels are going to look like the classic patient with hypercortisolism, with symptoms and signs but not the textbook picture of Cushing’s. It was Ana’s work to push forward to get a diagnosis and understand what was going on with her, which led to a diagnosis that might have been otherwise considerably delayed. https://lnkd.in/g5C3MegS
Grand Rounds, Episode 3: Disorders of Cortisol Secretion Related to Adrenal Conditions
https://www.youtube.com/
-
Thank you HCPLive for hosting this discussion. #hypercortisolism #type2diabetes
🚨 New #DiabetesDialogue! 🚨 Hear from John Buse, MD, PhD, as he discusses why he says the 2-part CATALYST trial might be the "biggest thing that I have ever done in my career" with Diana Isaacs, PharmD, BCPS, BCACP, BC-ADM, CDCES and Natalie Bellini, DNP, FNP-BC, BC-ADM, CDCES. Get a deep dive into the trial, including part 2, which will examine use of mifepristone (Korlym; Corcept Therapeutics) among patients who screened positive for hypercortisolism. https://lnkd.in/et4uQuDg #Type2Diabetes #Hypercortisolism
-
Our Patient Advocate, Jessica Behrend, RN, MSN, FNP-BC, shares more about her experience working with people with #Cushing’s Syndrome here: https://bit.ly/4cGYBHt #CushingsSyndrome #endocrinology #hypercortisolism
-
-
Our CATALYST trial examined the prevalence of #hypercortisolism among people with difficult-to-control type 2 #diabetes. Learn more in this article from Patrick Campbell at HCPLive: https://lnkd.in/gmFDQYF8 #ADA2024 #ADAScientificSessions #T2D
CATALYST Proves Hypercortisolism More Common than Previously Known in Type 2 Diabetes
hcplive.com
-
What began as a ripple of scientific truth is poised to unleash a sea change of discovery. Learn how: https://www.corcept.com/ #CortisolModulation #endocrinology #oncology #metabolism #neurology
-
Final results from the prevalence phase of our phase IV clinical trial study of hypercortisolism (Cushing’s syndrome) in patients with difficult-to-control type 2 diabetes were presented today at the American Diabetes Association 84th Scientific Sessions. Read more: https://lnkd.in/g_SbwHCT #CortisolModulation #Diabetes #Type2Diabetes #ADASciSessions #Hypercortisolism
-
-
Today at ADA our CATALYST data are being presented in the session: ADA Catalyst Plenary - Prevalence of Hypercortisolism in Difficult to Control Type 2 Diabetes. We look forward to the insightful discussion, which will be held in W415B (Valencia Ballroom) from 3:15pm – 4:15pm EDT. American Diabetes Association #CortisolModulation #Diabetes #ADASciSessions #Hypercortisolism
-
-
Are you driven by the idea of working in a scientific environment that offers both independence and open collaboration? Join us as we follow the data to unlock the potential of cortisol modulation to treat serious diseases. https://bit.ly/3V4V5PX #CortisolModulation #Endocrinology #Oncology
-